Applied Genetic Technologies’ $1 billion-plus gene therapy pact with Biogen has been torn up after their lead candidate failed a phase 1/2 trial.

Shareholders had accused Biofrontera of acting contrary to its duties when it priced and sold stock in the U.S.

The small phase 2 feasibility study linked fixed-dose combination NRX-101 to improved scores on a depression rating scale.

Scientists have early evidence that Amgen's oncolytic virus plus PD-1 and MEK inhibitors could be effective in treating melanoma.

GenSight has new data from its phase 3 program for its gene therapy for rare eye disease LHON, sparking another rise in its share price.

Akero will push a nonalcoholic steatohepatitis treatment licensed from Amgen through phase 2, and expand its pipeline.

The appointment means Gentile will commit full time to the autophagy startup he helped get off the ground.

The deal gives Lilly ownership of a small molecule that has inhibited tau aggregation in preclinical models.